Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9399 |
Menin-MLL inhibitor 20
|
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
Menin-MLL inhibitor 20 是一种不可逆的menin-MLL 相互作用抑制剂,具有抗肿瘤活性。 | |||
T2649 |
Menin-MLL inhibitor MI-2
Menin-MLL Inhibitor,MI2,MI-2,Menin-MLL inhibitor 2,MI 2 |
Apoptosis; Epigenetic Reader Domain; Histone Methyltransferase | Apoptosis; Chromatin/Epigenetic |
Menin-MLL inhibitor MI-2 (MI2) 抑制Menin-MLL 相互作用,IC50为 446±28 nM。 | |||
T2643 |
MI-3
Menin-MLL Inhibitor,Menin-MLL inhibitor 3,MI 3 |
Apoptosis; Epigenetic Reader Domain; Histone Methyltransferase | Apoptosis; Chromatin/Epigenetic |
MI-3 (Menin-MLL Inhibitor)是一种有高亲和力的 menin-MLL 抑制剂,IC50值为 648 nM,Kd 值为 201 nM。 | |||
T12002 |
Menin-MLL inhibitor 4
|
Others | Others |
Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction . | |||
T12943 |
SNDX-5613
|
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
SNDX-5613 是一种 Menin-MLL 特异性抑制剂,Ki 为 0.149 nM,IC50 为 10 在 20 nM 之间,可用于 MLL 基因重排的急性白血病研究。 | |||
T78151 |
Bleximenib oxalate
Menin-MLL inhibitor 24 oxalate |
Epigenetic Reader Domain | Chromatin/Epigenetic |
Bleximenib (Menin-MLL inhibitor 24) oxalate 是一种用于癌症研究的menin-mixed-lineage leukemia 1(menin-MLL)抑制剂。 | |||
T13336 |
VTP50469
|
Apoptosis; Epigenetic Reader Domain; Histone Methyltransferase | Apoptosis; Chromatin/Epigenetic |
VTP50469 是一种高选择性和口服活性的Menin-MLL 相互作用抑制剂,具有有效的抗白血病活性,Ki 为 104 pM。 | |||
T28036 |
MI-2-2
MI22,MI 2 2 |
Histone Methyltransferase | Chromatin/Epigenetic |
MI-2-2 是一种抑制 menin 和 MLL 之间二价蛋白质-蛋白质相互作用的抑制剂,IC50 为 46 nM。 MI-2-2 与 menin 结合,Kd 为 22 nM。 | |||
T69628 |
Iptacopan hydrochloride hydrate
|
||
Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor. | |||
T72360 |
Menin-MLL inhibitor 26
|
||
Menin-MLL inhibitor 26 是一种 Menin-MLL 抑制剂。Menin-MLL inhibitor 26 也是一个活性参照物。 Menin-MLL inhibitor 26 可以抑制细胞生长。Menin-MLL inhibitor 26 可用于白血病的研究。 | |||
T79117 |
Menin-MLL inhibitor 27
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
Menin-MLL inhibitor 27 是一种化合物,它能有效抑制Menin-MLL之间的相互作用,对于研究癌症具有潜在价值,尤其是在急性骨髓性白血病方面。 | |||
T79737 |
Menin-MLL inhibitor 29
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
Menin-MLL inhibitor 29(Compound C1)是一种选择性Menin-MLLPPI抑制剂。该化合物与Menin紧密结合,具有138 nM的KD值,并以46 nM的IC50值明显抑制Menin与MBM1(Menin结合motif 1)的相互作用。在体外条件下,Menin-MLL inhibitor 29对HepG2和Hep3B肝癌细胞系表现出抑制增殖的作用(IC50s分别为0.31 μM和0.71 μM),也能有效抑制肿瘤生长。 | |||
T72135 |
(1s,4s)-Menin-MLL inhibitor-23
|
||
(1s,4s)-Menin-MLL inhibitor-23 是Menin-MLL inhibitor-23 的对应异构体。Menin-MLL inhibitor-23 (Example 99A) 是一种menin-MLL 相互作用抑制剂。 | |||
TQ0069 |
MI-503
|
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
MI-503 是一种高效且可口服的 menin-mLL 相互作用抑制剂。 | |||
T16072 |
MI-538
|
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
MI-538是一种menin 和MLL 融合蛋白相互作用的抑制剂,IC50值为 21 nM。 | |||
T11925 |
M‑89
|
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
M-89 可抑制 Menin-MLL 蛋白之间的相互作用,有研究混合谱系白血病的潜力。它是一种强特异性 menin 抑制剂,结合到 menin 的Kd 值为 1.4 nM。 | |||
TQ0058 |
MI-463
|
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
MI-463 是一种有口服活性的menin-mLL 相互作用的高效小分子抑制剂,IC50为15.3 nM。 | |||
T39585 |
Ziftomenib
KO-539 |
Histone Methyltransferase | Chromatin/Epigenetic |
Ziftomenib (KO-539) 是一种具有抗肿瘤活性的 menin-MLL 相互作用抑制剂,可以用于研究白血病。 | |||
T6889 |
MI-136
|
Apoptosis; Epigenetic Reader Domain; Androgen Receptor | Apoptosis; Chromatin/Epigenetic; Endocrinology/Hormones |
MI136 是 menin-MLL(PPI) 蛋白互作的抑制剂,其 IC50值为31 nM,Kd 值为23.6 nM。它可抑制 DHT 诱导的雄激素受体 (AR) 靶基因的表达,有用于去势抵抗性肿瘤的潜能。 | |||
T39937 |
M-808
|
||
M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM. | |||
T15831 |
M-525
|
Others | Others |
M-525 binds to menin (IC50: 3 nM) and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL regulated gene expression in MLL leukemia cells. M-525 is a first-in-class, highly potent, irreversible, and covalent menin-MLL | |||
T39938 |
M-1211
|
||
M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression. | |||
T61735 |
MI-1
|
||
MI-1 抑制 Menin-MLL 相互作用,IC50为 1.9 μM。 | |||
T22978 | MI-2 (hydrochloride) | Others | Others |
MI-2 (Menin-MLL Inhibitor) is an effective menin-MLL interaction inhibitor (IC50: 446 ± 28 nM). | |||
T27134 |
DCYM21
DC YM 21,DC-YM21,DCYM-21,DC_YM21,DC YM21 |
||
DCYM21 is an inhibitor of menin-MLL interaction. DCYM21 demonstrates potent and selective blockage of proliferation and induces both cell cycle arrest and differentiation of leukemia cells harboring MLL translocations. | |||
T24472 |
MIV-6R
MIV6R,VU05163101,VU0516310-1,VU0516310 1,MIV 6R |
||
MIV-6R is an inhibitor of the menin- MLL interaction that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanisms of action. | |||
T24484 |
ML399
VU-0516340,VU 0516340,ML-399,VU0516340,ML 399 |
||
ML399 is the menin-- MLL interaction inhibitor that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanism of action. | |||
T69629 | M‑89 MLL inhibitor | ||
M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular menin protein at low nanomolar concentrations. M-89 inhibits cell growth in the MV4;11 and MOLM-13 leukemia cell lines carrying MLL fusion with IC50 values of 25 and 55 nM, respectively, and demonstrates >100-fold selectivity over the HL-60 leukemia cell line lacking MLL fusion. | |||
T13336L |
VTP50469 fumarate
|
Others | Others |
VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity. | |||
T24463 |
MI-1481
MI 1481 |
||
MI-1481 is an effective MML1 inhibitor (IC50: 3.6 nM). MI-1481 showed very potent inhibition of the menin-MLL1 interaction (IC50: 3.6 nM). MI-1481 also demonstrates pronounced activity in MLL leukemia cells and in vivo in MLL leukemia models. |